Galecto, Inc. (GLTO)
NASDAQ: GLTO · Real-Time Price · USD
2.650
-0.250 (-8.62%)
At close: Apr 28, 2025, 4:00 PM
2.680
+0.030 (1.13%)
After-hours: Apr 28, 2025, 5:27 PM EDT

Company Description

Galecto, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases.

The company develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications.

Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Galecto, Inc.
Galecto logo
Country Denmark
Founded 2011
IPO Date Oct 29, 2020
Industry Biotechnology
Sector Healthcare
Employees 5
CEO Hans Schambye

Contact Details

Address:
Ole Maaloes Vej 3, Copenhagen N
Copenhagen, 2200
Denmark
Phone 45 70 70 52 10
Website galecto.com

Stock Details

Ticker Symbol GLTO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $15.00
CIK Code 0001800315
CUSIP Number 36322Q107
ISIN Number US36322Q1076
Employer ID 37-1957007
SIC Code 2834

Key Executives

Name Position
Dr. Hans T. Schambye M.D., Ph.D. Co-Founder, President, Chief Executive Officer and Director
Garrett Winslow Esq. Senior Vice President, General Counsel and Corporate Secretary
Ulf J. Nilsson Ph.D. Co-Founder
Dr. Hakon Leffler M.D., Ph.D. Co-Founder
Prof. Tariq Sethi B.Sc., FRCP, M.A., M.D., Ph.D. Co-Founder
Lori C. Firmani Interim Chief Financial Officer
Matthew Kronmiller Executive Vice President of Strategy and Chief Business Officer

Latest SEC Filings

Date Type Title
Apr 17, 2025 PRE 14A Other preliminary proxy statements
Mar 19, 2025 S-8 Securities to be offered to employees in employee benefit plans
Mar 19, 2025 10-K Annual Report
Jan 16, 2025 SCHEDULE 13D/A Filing
Nov 7, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 7, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 1, 2024 10-Q Quarterly Report
Oct 15, 2024 8-K Current Report
Oct 7, 2024 8-K Current Report
Sep 18, 2024 8-K Current Report